Patrick Lundgren joined Flagship Pioneering in 2022 as an Associate and is a graduate of the Flagship Fellowship class of 2021. Patrick works as part of a team of entrepreneurial scientists to explore new areas of biology and develop the science, intellectual property, and business strategy for Flagship’s breakthrough bioplatform companies.
Patrick completed his Ph.D. in immunology at the University of Pennsylvania, following studies at Cambridge and Oxford. His scientific interests have been anchored in the broad question of how animals respond to environmental challenges. In his Ph.D. he applied methods for unbiased measurement of transcriptomic and metabolomic features in tissues to understand responses to environmental perturbations such as cold temperature exposure, diet, and host-microbiome interactions. Patrick was awarded a Ruth L. Kirschstein pre-doctoral National Research Service Award from the NHLBI and his work has resulted in multiple publications, including in Cell and Nature.
While in his Ph.D., he co-founded NanoXCell Therapeutics, a Penn spinout aiming to re-invent the way that immune cells are engineered using a non-viral nanotechnology platform with vision to create single cell CAR T cell therapies.
In addition to his Ph.D., Patrick holds an M.Sc. in immunology from the University of Oxford (with Distinction), and a B.A. (Hons) in Natural Sciences from the University of Cambridge.